Staff Reports
The Susan B. Anthony Pro‑Life America has just taken its case to the U.S. Supreme Court — and it did so with a blunt message: the abortion pill era that lets pills be prescribed by telehealth and mailed to anyone creates an “unregulated Wild West” where real informed consent is impossible. The group filed an amicus brief asking the Court to reject drugmakers’ bid to block a lower‑court order that would bring back in‑person doctor visits for mifepristone.
What SBA Just Filed
Susan B. Anthony Pro‑Life America, led by President Marjorie Dannenfelser, filed an amicus brief urging the Supreme Court to stop the drug companies from short‑circuiting what SBA calls commonsense safety rules. The brief argues that anyone can order the abortion pill online, have it shipped across state lines, and even stockpile it — all without a doctor ever seeing the patient in person. SBA joins a chorus of states and lawmakers asking the Court to let in‑person medical evaluations be reinstated while the appeals play out.
Why SBA Says In‑Person Visits Matter
The heart of SBA’s argument is simple: informed consent is not just a form, it’s a real conversation and an exam. Their brief says an in‑person visit helps screen for coercion, serious health risks, and other problems that a video call or a questionnaire might miss. SBA points to research from pro‑life research groups alleging higher rates of serious adverse events and emergency‑department visits after medication abortions, and it uses stories of women who suffered to make the human case. If you prefer short answers over sciency caveats, that is their bottom line.
The Medical Community and FDA Push Back
Not everyone agrees. Major medical societies and the FDA say the scientific record supports telehealth prescriptions and mail or pharmacy dispensing of mifepristone. Groups like the American College of Obstetricians and Gynecologists argue the pill is safe when prescribed via telehealth, and they have filed their own briefs defending the FDA’s 2023 change to REMS rules. So this is not a clean tug‑of‑war: it’s a fight over which studies and stories the Court trusts — and whether safety or access wins in the short term.
What the Supreme Court Must Decide Next
The immediate question for the Court is procedural but consequential: will it extend an administrative stay that currently keeps the FDA’s 2023 policy in place, or will it allow the Fifth Circuit’s reinstatement of an in‑person requirement to take effect while the merits are litigated? Drugmakers Danco and GenBioPro want the stay extended so telehealth and mail delivery can continue. SBA and other states want the in‑person rule back while appeals proceed. The Court’s next move will change how mifepristone is prescribed across the country — not down the road, but right away.
Call it what you will — safety versus access, caution versus convenience — this fight is now at the Supreme Court. Conservatives who care about protecting women and ensuring honest medical consent should welcome a close look at how the abortion pill is being distributed. If the “Wild West” description sounds harsh, that’s because it is: when powerful drugs can be shipped anonymously to any doorstep, that invites profit, mistakes, and abuse. The justices will have to weigh evidence, stories, and science — and decide whether in‑person medicine still matters in a world that increasingly prefers a click and a delivery truck.
